Clover Corporation Limited (ASX:CLV): FY26 Nutrition Ingredients Revenue and Product Development

Aditi Sarkar

09 October 2026 10:21 PM AEDT

Clover Corporation Limited (ASX:CLV): FY26 Nutrition Ingredients Revenue and Product Development

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Clover Corporation reported FY26 Revenue of $97.4 million for the year ended 31 July 2026.
Net profit after tax reached $10.5 million, reflecting the company’s reported operating result.
Product development includes microencapsulated nutritional powders and specialist fatty-acid ingredients.
Demand across infant nutrition and other food applications remains relevant to sales mix.
Input costs, customer requirements and Manufacturing performance remain key operating considerations.

Clover Corporation Limited (ASX:CLV) develops and supplies nutritional ingredients for food and human nutrition applications, including specialised oils and microencapsulated powders. Its 2026 reporting highlights how product mix, manufacturing performance and customer Demand affect revenue and profitability, while its ingredient technology remains central to the business.

FY26 Revenue and Earnings

For the financial year ended 31 July 2026, Clover Corporation Limited (ASX:CLV) reported revenue of $97.4 million. The company also reported net profit after tax of $10.5 million in its full-year results. These figures provide a measurable view of the scale and profitability of its specialist ingredient activities during FY26.

The company attributed its financial performance to demand for microencapsulated powders, product Diversification and changes in operating margins. For ASX:CLV, developments in the composition of sales can matter alongside overall sales volumes because ingredient categories have different production requirements and commercial characteristics.

How Nutritional Encapsulation Supports the Business

Clover supplies nutritional lipid ingredients that can be incorporated into products such as infant formula and other food applications. Microencapsulation enables selected oils to be formulated as powders for use in food manufacturing. This gives customers another means of including specific fatty-acid ingredients in finished products.

Through its nutrition ingredient activities, ASX:CLV is exposed to demand for formulations containing docosahexaenoic acid (DHA) and arachidonic acid (ARA). Product specifications, stability, compliance with customer requirements and manufacturing consistency can influence commercial acceptance. The company’s FY26 material also identifies demand for newer products, including ARA powders, as relevant to its product mix.

Manufacturing and Supply Chain Considerations

Clover Corporation Limited (ASX:CLV) operates in an ingredient market where raw-material availability and quality control are important. Its supply chain includes marine-derived oils and other nutritional inputs, while its processing and encapsulation activities add further manufacturing stages before products reach food manufacturers.

The FY26 annual reporting describes improved manufacturing performance and diversification of the product mix. These developments are relevant to gross margin, although changes in ingredients, production costs or customer orders can alter the outcome in subsequent reporting periods. ASX:CLV also faces practical requirements associated with ingredient traceability, finished-product specifications and international distribution.

Operating Factors and Commercial Risks

The financial performance of a specialist ingredient supplier can be affected by demand from a relatively concentrated customer base, the timing of customer production schedules and the cost of raw oils. Changes to infant nutrition standards or Import requirements may also influence formulation decisions and approval processes.

For Clover Corporation Limited (ASX:CLV), maintaining product quality while managing costs and customer relationships remains an operational consideration. Changes in end-market demand can affect orders without implying an equivalent change in long-term use of nutritional ingredients.

Key Insights

Clover’s FY26 results show a Business centred on specialised nutrition products rather than conventional Commodity oils. Reported revenue of $97.4 million and net profit after tax of $10.5 million offer a financial snapshot, while product mix, manufacturing execution and customer ordering patterns provide context for future company disclosures. The distinction between nutritional inputs and petroleum commodities is important when assessing the business model of ASX:CLV.

FAQs

Q: What does Clover Corporation manufacture?

A:It develops and supplies nutritional oils and microencapsulated powders for food and human nutrition markets.

Q: What revenue did the company report for FY26?

A:Clover reported revenue of $97.4 million for the year ended 31 July 2026.

Q: What was its reported FY26 net profit after tax?

A:The company reported net profit after tax of $10.5 million.

Q: What ingredients feature in Clover’s product offering?

A:Its products include nutritional fatty-acid ingredients such as DHA and ARA.

Q: Which operating factors are relevant?

A:Customer demand, ingredient input costs, manufacturing performance and product requirements can influence operations.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.